Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation
Autore:
Murray, RD; Deitcher, SR; Shah, A; Jasper, SE; Bashir, M; Grimm, RA; Klein, AL;
Indirizzi:
Cleveland Clin Fdn, Dept Cardiol, Cardiovasc Imaging Sect, Cardiovasc Imaging Ctr, Cleveland, OH 44195 USA Cleveland Clin Fdn Cleveland OH USA 44195ng Ctr, Cleveland, OH 44195 USA Cleveland Clin Fdn, Dept Vasc Med, Clin Thrombosis Sect, Cleveland, OH 44195 USA Cleveland Clin Fdn Cleveland OH USA 44195 s Sect, Cleveland, OH 44195 USA Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA Cleveland Clin Fdn Cleveland OH USA 44195 demiol, Cleveland, OH 44195 USA
Titolo Testata:
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
fascicolo: 3, volume: 14, anno: 2001,
pagine: 200 - 208
SICI:
0894-7317(200103)14:3<200:PCEACB>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEEP-VEIN THROMBOSIS; UNFRACTIONATED HEPARIN; ELECTIVE CARDIOVERSION; ANTICOAGULANT-THERAPY; ECONOMIC-ANALYSIS; PREVENTION; DISEASE; COMPLICATIONS; MANAGEMENT; SURGERY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Klein, AL Cleveland Clin Fdn, Dept Cardiol, Cardiovasc Imaging Sect, Cardiovasc Imaging Ctr, Desk F-15,9500 Euclid Ave, Cleveland, OH 44195 USA Cleveland Clin Fdn Desk F-15,9500 Euclid Ave Cleveland OH USA 44195
Citazione:
R.D. Murray et al., "Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation", J AM S ECHO, 14(3), 2001, pp. 200-208

Abstract

An alternative clinical management strategy and cost analysis model is presented for patients with atrial fibrillation of >2 days' duration who may benefit from immediate cardioversion with self-administered low-molecular-weight heparin (enoxaparin) as a bridge antithrombotic therapy to warfarin, after a negative transesophageal echo-cardiography (TEE) screening for thrombus. Assuming no difference in stroke or bleeding rates, our cost minimization model shows that the TEE-guided enoxaparin treatment costs are $1353 lower per patient than an Intravenous unfraction-ated heparin approach. Sensitivity analyses for stroke and bleeding reveal that the treatment-cost economic dominance of the TEE-guided enoxaparin approach may be enhanced by an expected improvement in clinical outcome.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 15:29:28